Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$1.25
>-$0.01(-4.03%)
At close: 4:00 PM EST
$1.25
>-$0.01(-4.03%)
Day’s Range― - ―
52-Week Range$0.21 - $20.33
Previous CloseN/A
Volume272.06K
Average Volume (3M)56.65M
Market Cap
$7.76M
Enterprise Value$119.42K
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$4.57M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding27,724,245
10 Day Avg. Volume13,781,055
30 Day Avg. Volume56,653,307
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit-0.96
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside320.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Restored NYSE Compliance And Fresh CapitalRegaining NYSE American compliance and raising roughly $8.5M materially reduce immediate delisting risk and provide multi-month runway to advance clinical programs. Improved listing status bolsters governance credibility and access to institutional investors, supporting durable operational continuity.
Promising Clinical Signals For Lead Candidate AmpligenClinical signals, KOL endorsement and peer-reviewed publications strengthen Ampligen's scientific credibility in pancreatic cancer. Orphan designations and human safety data create a structural pathway for regulatory incentives and focused development, raising the long-term potential of a commercially meaningful therapy if trials confirm benefits.
Modest Formal Leverage On Balance SheetLow reported debt limits fixed financing obligations, preserving optionality to fund clinical milestones with equity or non-debt instruments. This structural low-leverage position reduces bankruptcy risk from interest burdens and allows management to prioritize R&D investment choices over debt service constraints in the coming months.
Bears Say
Persistent High Cash BurnSustained negative operating and free cash flow implies AIM must repeatedly access external capital to continue operations. This structural cash deficit constrains strategic flexibility, increases refinancing risk, and forces prioritization of near-term funding over longer-term programs absent durable revenue or large financing commitments.
Minimal Commercial Revenue And Deep LossesWith effectively no commercial revenue, AIM remains fully dependent on successful clinical outcomes and external funding. The lack of a revenue foundation lengthens the path to self-sustainability, magnifies binary clinical risk and means operational continuity hinges on successful trial readouts or recurring financings over the medium term.
Structural Reliance On Equity/warrant FinancingsFrequent use of warrant inducements, registered directs, and expanded ATM capacity signals reliance on dilutive equity tools. This durable financing pattern increases shareholder dilution risk, creates potential overhang from outstanding warrants, and may impair long-term investor confidence absent a clear path to revenue or less dilutive funding sources.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $0.21 and its highest was $20.33 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $7.76M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 42 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Currently, no data Available
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate is -0.17.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 27,724,245 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM Stock 12 Month Forecast
Average Price Target
$5.25
▲(320.00% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
0.10% Mutual Funds
<0.01% Other Institutional Investors
99.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---